Умизортамиг

Rec. INN (наименование, зарегистрированное ВОЗ)

2599198-83-9

immunoglobulin scFv-G1-scFv-scFv_L-kappa, anti-[Homo sapiens EGFRvIII (epidermal growth factor receptor (receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB) variant III)], anti-[Homo sapiens CD3E (CD3 epsilon, Leu-4) and CD3G], anti-[Homo sapiens CD274 (programmed cell death 1 ligand 1, B7H1, B7-H1, PDL1, PD-L1, PDCD1L1, B7 homolog 1, B7 homologue 1)] and anti-[Homo sapiens TNFRSF9 (tumor necrosis factor receptor (TNFR) superfamily member 9, 4-1BB, T cell antigen ILA, CD137 (4-1BB, CD137). 41BB)], humanized and chimeric monoclonal antibody, tetraspecific, tetravalent;
scFv-G1-scFv-scFv fused heavy chain humanized and chimeric (1-1231) [scFv kappa-heavy anti-CD3E and CD3G humanized (1-252) [V-KAPPA (Homo sapiens IGKV1-5*01 (90.1%) -IGKJ4*01 (90.9%), CDR-IMGT [6.3.14] (27-32.50-52.89-102)) (1-112) -20-mer tetrakis(tetraglycyl-seryl) linker (113-132) -VH (Homo sapiens IGHV3-66*01 (86.6%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.7.14] (158-165.183-189.228-241)) (133-252)] -10-mer bis(tetraglycyl-seryl) linker (253-262) -gamma-1 heavy chain anti-EGFRvIII chimeric (263-707) [VH Musmus/Homsap (Mus musculus IGHV3-2*02 (94.82%) -(IGHD) -IGHJ3*01 (92.9%)/Homo sapiens IGHV4-30-4*01 (72.9%) -(IGHD) -IGHJ4*01 (85.7%), CDR-IMGT [9.7.9] (288-296.314-320.359-367)) (263-378) -Homo sapiens IGHG1*01v, G1m17,1>G1m3,1, G1v14-1 CH2 A1.3, A1.2, A1, G1v20 CH2 A105 (CH1 R120 (475) (379-476), hinge 1-15 (477-491), CH2 L1.3>A (495), L1.2>A (496), G1>A (498), K105>A (583) (492-601), CH3 D12 (617), L14 (619) (602-706), CHS K2>del (707)) (379-707)] -10-mer bis(tetraglycyl-seryl) linker (708-717) -scFv heavy-kappa anti-CD274 humanized (718-969) [VH (Homo sapiens IGHV3-23*01 (84.0%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [9.9.13] (743-751.769-777.816-828)) (718-839) -20-mer tetrakis(tetraglycyl-seryl) linker (840-859) -V-KAPPA (Homo sapiens IGKV1-5*03 (91.5%) -IGKJ4*01 (100%), CDR-IMGT [6.3.12] (886-891.909-911.948-959)) (860-969)] -10-mer bis(tetraglycyl-seryl) linker (970-979) -scFv heavy-kappa anti-TNFRSF9 humanized (980-1231) [VH (Homo sapiens IGHV3-66*01 (85.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [9.9.12] (1004-1012.1030-1038.1077-1088)) (980-1099) -20-mer tetrakis(tetraglycyl-seryl) linker (1100-1119) -V-KAPPA (Homo sapiens IGKV1-5*03 (87.2%) -IGKJ4*01 (100%), CDR-IMGT [6.3.14] (1146-1151.1169-1171.1208-1221)) (1120-1231)]]; (481-214')-disulfide with kappa light chain anti-EGFRvIII chimeric (1'-214') [V-KAPPA Musmus/Homsap (Mus musculus IGKV14-100*01 (93.7%) -IGKJ1*01 (100%)/Homo sapiens IGKV1-12*01 (63.2%) -IGKJ4*01 (90.9%), CDR-IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (487-487'':490-490'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Поделиться этой страницей